Schlegel Birgit, Laggner Christian, Meier Rene, Langer Thierry, Schnell David, Seifert Roland, Stark Holger, Höltje Hans-Dieter, Sippl Wolfgang
Institute of Pharmaceutical Chemistry, Heinrich-Heine-Universität Düsseldorf, Universitätsstr 1, 40197, Dusseldorf, Germany.
J Comput Aided Mol Des. 2007 Aug;21(8):437-53. doi: 10.1007/s10822-007-9127-x. Epub 2007 Aug 1.
The human histamine H(3) receptor (hH(3)R) is a G-protein coupled receptor (GPCR), which modulates the release of various neurotransmitters in the central and peripheral nervous system and therefore is a potential target in the therapy of numerous diseases. Although ligands addressing this receptor are already known, the discovery of alternative lead structures represents an important goal in drug design. The goal of this work was to study the hH(3)R and its antagonists by means of molecular modelling tools. For this purpose, a strategy was pursued in which a homology model of the hH(3)R based on the crystal structure of bovine rhodopsin was generated and refined by molecular dynamics simulations in a dipalmitoylphosphatidylcholine (DPPC)/water membrane mimic before the resulting binding pocket was used for high-throughput docking using the program GOLD. Alternatively, a pharmacophore-based procedure was carried out where the alleged bioactive conformations of three different potent hH(3)R antagonists were used as templates for the generation of pharmacophore models. A pharmacophore-based screening was then carried out using the program Catalyst. Based upon a database of 418 validated hH(3)R antagonists both strategies could be validated in respect of their performance. Seven hits obtained during this screening procedure were commercially purchased, and experimentally tested in a [(3)H]N(alpha)-methylhistamine binding assay. The compounds tested showed affinities at hH(3)R with K ( i ) values ranging from 0.079 to 6.3 muM.
人类组胺H(3)受体(hH(3)R)是一种G蛋白偶联受体(GPCR),它可调节中枢和外周神经系统中多种神经递质的释放,因此是众多疾病治疗中的一个潜在靶点。尽管已经有针对该受体的配体,但发现替代的先导结构仍是药物设计中的一个重要目标。这项工作的目的是通过分子建模工具研究hH(3)R及其拮抗剂。为此,采用了一种策略,即基于牛视紫红质的晶体结构生成hH(3)R的同源模型,并在二棕榈酰磷脂酰胆碱(DPPC)/水膜模拟体系中通过分子动力学模拟对其进行优化,然后将所得的结合口袋用于使用GOLD程序进行高通量对接。另外,还进行了基于药效团的操作,将三种不同强效hH(3)R拮抗剂的假定生物活性构象用作生成药效团模型的模板。然后使用Catalyst程序进行基于药效团的筛选。基于418种经过验证的hH(3)R拮抗剂的数据库,两种策略的性能均可得到验证。在该筛选过程中获得的7个命中化合物进行了商业购买,并在[(3)H]N(α)-甲基组胺结合试验中进行了实验测试。测试的化合物在hH(3)R上显示出亲和力,其K(i)值范围为0.079至6.3 μM。